Aridis Pharmaceuticals (ARDS) to Release Quarterly Earnings on Friday

Aridis Pharmaceuticals (NASDAQ:ARDS) is expected to announce its resultson Friday, June 12th. Analysts expect the company to announce earnings of ($0.6275) per share and revenue of $0.45 million for the quarter.

Aridis Pharmaceuticals Price Performance

NASDAQ ARDS opened at $0.00 on Friday. The company has a market capitalization of $10,664.20, a price-to-earnings ratio of 0.00 and a beta of 49.37. Aridis Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.05.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals is a San Diego–based clinical-stage biotechnology company dedicated to developing immunotherapeutic products for the prevention and treatment of life-threatening bacterial and fungal infections. The company’s technology platform leverages monoclonal antibodies and inhaled antifungal formulations to address antibiotic-resistant respiratory pathogens and emerging inhalational threats. Aridis’ research focuses on targeting key virulence factors in organisms such as Pseudomonas aeruginosa and Staphylococcus aureus, with the aim of delivering novel therapeutic approaches for hospital-acquired and ventilator-associated pneumonias, catheter-related bloodstream infections and deep fungal infections of the lung.

Among the company’s pipeline candidates, AR-310 is a first-in-class inhaled monoclonal antibody against Pseudomonas aeruginosa, designed for both prophylactic and therapeutic use in patients with cystic fibrosis and those at high risk of ventilator-associated pneumonia.